Conclusions: chronic pain studies of lidocaine patch 5% using the Neuropathic Pain Scale

被引:11
作者
Argoff, CE [1 ]
机构
[1] NYU, Sch Med, N Shore Univ Hosp, Cohn Pain Management Ctr, Bethpage, NY 11714 USA
关键词
analgesics; Neuropathic Pain Scale; pain assessment; pain scale;
D O I
10.1185/030079904X12979
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many chronic pain patients have multiple etiologies for their pain, and accurate characterization of pain qualities and pain relief is essential for managing their pain. The ability to utilize a validated tool for assessing pain qualities and for identifying unique analgesic therapy effects on different pain qualities may assist clinicians in devising an appropriate treatment regimen. The Neuropathic Pain Scale (NPS) is a novel pain metric for characterizing pain in 10 dimensions. The ability to differentiate among pain qualities for each patient may result in a more refined and effective choice of therapy. The three research articles in this Supplement demonstrate the utility of the NPS in chronic pain patients treated with the lidocaine patch 5%, a peripherally acting medication that is not associated with systemic accumulation of the active drug(1-3). Significant reduction in the intensity of commonly reported pain qualities in patients with neuropathic and non-neuropathic chronic pain due to low-back pain, osteoarthritis, post-herpetic neuralgia, and painful diabetic neuropathy were achieved. The NPS offers clinicians a reliable means to accurately identify pain qualities associated with each individual patient and to target and assess the efficacy of various therapeutic options on those pain components. Utilizing the NPS, the lidocaine patch 5% was effective in treating chronic pain of both neuropathic and non-neuropathic origins suggesting that a given treatment's effect on various pain qualities may be consistent across pain types.
引用
收藏
页码:S29 / S31
页数:3
相关论文
共 13 条
[1]   Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale [J].
Argoff, CE ;
Galer, BS ;
Jensen, MP ;
Oleka, N ;
Gammaitoni, AR .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 :S21-S28
[2]  
BIGOS SJ, 1995, AM FAM PHYSICIAN, V51, P469
[3]   CLINICAL COURSE AND PROGNOSTIC FACTORS IN ACUTE LOW-BACK-PAIN - AN INCEPTION COHORT STUDY IN PRIMARY-CARE PRACTICE [J].
COSTE, J ;
DELECOEUILLERIE, G ;
DELARA, AC ;
LEPARC, JM ;
PAOLAGGI, JB .
BRITISH MEDICAL JOURNAL, 1994, 308 (6928) :577-580
[4]   Primary care - Low back pain [J].
Deyo, RA ;
Weinstein, JN .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :363-370
[5]   Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain [J].
Galer, BS ;
Gammaitoni, AR ;
Oleka, N ;
Jensen, MP ;
Argoff, CE .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 :S5-S12
[6]   Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study [J].
Galer, BS ;
Rowbotham, MC ;
Perander, J ;
Friedman, E .
PAIN, 1999, 80 (03) :533-538
[7]   The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale [J].
Galer, BS ;
Jensen, MP ;
Ma, T ;
Davies, PS ;
Rowbotham, MC .
CLINICAL JOURNAL OF PAIN, 2002, 18 (05) :297-301
[8]   Development and preliminary validation of a pain measure specific to neuropathic pain: The neuropathic pain scale [J].
Galer, BS ;
Jensen, MP .
NEUROLOGY, 1997, 48 (02) :332-338
[9]   Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale [J].
Gammaitoni, AR ;
Galer, BS ;
Onawola, R ;
Jensen, MP ;
Argoff, CE .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 :S13-S19
[10]   Pharmacokinetics and safety of continuously applied lidocaine patches 5% [J].
Gammaitoni, AR ;
Alvarez, NA ;
Galer, BS .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (22) :2215-2220